The Spanish Ministry of Science, Innovation and Universities, through the Centre for the Development of Industrial Technology (CDTI), and the European Investment Fund (EIF) have announced a joint investment of €74.7 million in the Asabys Innvierte Tech Transfer fund. Managed by Asabys Partners, the fund is designed to support innovation and company creation in biotechnology, medical technologies, and deep-tech health solutions across Spain.
The investment forms part of the Innvierte Deep Start framework, a financial instrument created by CDTI and the EIF to mobilize public-private investment in high-impact deep-tech projects. The Asabys Innvierte Tech Transfer fund is targeting a total size of up to €120 million and will focus on supporting very early-stage projects emerging from universities, hospitals, and research centres. The initiative aims to strengthen technology transfer and transform scientific research into commercially viable healthcare innovations.
The fund will invest in the creation of academic spin-offs, pre-seed ventures, and projects that require support to reach proof of concept and industrial development stages. Organizers stated that the initiative will prioritize innovative technologies such as artificial intelligence, supercomputing, synthetic biology, advanced materials, and new therapeutic modalities applied to healthcare and life sciences.
Officials noted that the investment aligns with Spain’s National Deep Tech Strategy 2026–2030, which seeks to strengthen the country’s innovation ecosystem and increase the commercialization of scientific research. The broader Innvierte Deep Start programme has a total funding allocation of €353 million, including €300 million from the Spanish Ministry through CDTI and €53 million from the EIF. The strategy aims to improve early-stage financing and reinforce Spain’s position as a leading destination for deep-tech investment in Europe.
Asabys Partners, headquartered in Barcelona, specializes in health innovation and life sciences investments. The firm currently manages more than €400 million in assets and focuses on biotechnology, medical technology, and digital health startups. According to company representatives, the new fund will take an active role in identifying promising research projects and helping build companies from the ground up by supporting business development, management formation, and commercialization pathways.
The European Investment Fund emphasized that technology transfer and venture capital are essential for strengthening Europe’s innovation capacity and competitiveness. EIF and CDTI officials stated that the co-investment model is intended to attract additional international investment into Spanish startups and expand opportunities for disruptive scientific innovation with strong economic and social impact.
